Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMT Lotion in Atopic Dermatitis
NCT03151148Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2017
- Primary completion
- May 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing TMT Lotion with Placebo Lotion (2 arms). Primary endpoint: Per-Participant Daily Event Rate: Serious and Non-Serious Treatment Emergent Adverse Events. Started Sep 2017; status: completed.
02
Drugs
Staphylococcus hominis A9
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03151148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151148.